Voltage-dependent calcium channel subunit beta (Cavβ)

The voltage-dependent calcium channel subunit beta (Cavβ) is a critical cytosolic auxiliary component of high-voltage-activated (HVA) calcium channels, including L-, N-, P/Q-, and R-types [1, 3]. It belongs to the membrane-associated guanylate kinase (MAGUK) protein family and consists of four isoforms (β1–β4) that play a dual role in channel regulation [3, 12]. Primarily, Cavβ acts as a molecular chaperone, facilitating the trafficking of the pore-forming alpha-1 (α1) subunit from the endoplasmic reticulum to the plasma membrane, thereby increasing functional channel density [3, 11]. Additionally, it significantly modulates the biophysical properties of the channel, such as the voltage dependence of activation and the kinetics of inactivation [1, 16]. Mutations in Cavβ genes are linked to various channelopathies, including Brugada syndrome, episodic ataxia, and certain forms of epilepsy [6, 13]. While most clinical calcium channel blockers target the α1 subunit, Cavβ is an emerging therapeutic target for pain, cardiovascular disorders, and neuropsychiatric conditions, with research focusing on small molecules that disrupt the α-β subunit interface [2, 13].

Other names

CavβCACNBCalcium channel beta subunitVoltage-gated calcium channel auxiliary subunit betaCACNB1CACNB2CACNB3CACNB4

Cavβ subunits act by binding to the alpha-interaction domain (AID) of the pore-forming alpha-1 subunit, which masks an endoplasmic reticulum retention signal and promotes trafficking to the cell surface [3, 12]. They also modulate channel gating by shifting the voltage-dependence of activation and altering inactivation kinetics [1, 16]. Drugs targeting this subunit, such as the experimental compound IPPQ, work by disrupting the alpha-beta subunit interface to inhibit calcium currents [2].